The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of 8 months of afatinib switching to osimertinib (A) versus osimertinib alone (B) as first-line treatment in advanced NSCLC patients with common EGFR mutation: YAMATO study (TORG1939/WJOG12919L).
 
Atsushi Nakamura
No Relationships to Disclose
 
Hiroshige Yoshioka
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Lilly; Merck; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Delta-Fly Pharma
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Delta-Fly Pharma (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst)
 
Toshihiro Misumi
No Relationships to Disclose
 
Toshihide Yokoyama
No Relationships to Disclose
 
Hidetoshi Itani
No Relationships to Disclose
 
Motoko Tachihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; takeda
Research Funding - AstraZeneca (Inst)
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Akira Ono
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Janssen Research & Development (Inst)
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Takaaki Tokito
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Chugai Pharma; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Masahide Mori
Speakers' Bureau - Abbvie; Astrazeneca; Boehringer Ingelheim; Chugai Pharma; Daiici-Sankyo; Kyowa-kirin; Lilly; MSD; Nihonkayaku; Ono pharmacoceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst)
 
Takehiro Uemura
No Relationships to Disclose
 
Akito Hata
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hideki Ishikawa
No Relationships to Disclose
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Mebix (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroaki Okamoto
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Janssen; MSD Oncology (Inst); Takeda (Inst)